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Abstract 
Objective: This present study aims to address the gap in the literature regarding the 
severity and underlying neural correlates of psychotic symptoms in frontotemporal 
dementia with and without the C9orf72 gene expansion.  
Methods: Fifty-six patients with behavioural variant frontotemporal dementia (20 with 
concomitant amyotrophic lateral sclerosis) and 23 healthy controls underwent 
neuropsychological assessments, detailed clinical interview for assessment of psychosis 
symptoms, brain MRI and genetic testing. Carers underwent a clinical interview based 
upon the neuropsychiatric inventory. Patients were assessed at ForeFront, the 
Frontotemporal Dementia Research Group at Neuroscience Research Australia or at the 
Brain and Mind Centre, between January 2008 and December 2013.   
An index of psychosis was calculated, taking into account the degree and severity of 
psychosis in each case. Voxel-based morphometry analyses were used to explore 
relationships between the psychosis index and grey matter changes.  
Results: Thirty-four percent of frontotemporal dementia patients showed psychotic 
features. C9orf72 expansion cases were more likely to exhibit psychotic symptoms than 
non-carriers (64% vs. 26%; p = 0.006), which were also more severe (psychotic index 
23.1 vs. 8.1; p = 0.002).  Delusions comprised persecutory, somatic, jealous and grandiose 
types and were present in 57% of C9orf72 carriers and 19% of non-carriers (p = 0.006). 
Auditory, visual or tactile hallucinations were present in 36% of C9orf72 carriers and 17% 
of non-carriers (p = 0.13). Increased psychotic symptoms in C9orf72 expansion carriers 
correlated with atrophy in a distributed cortical and subcortical network that included 
discrete regions of the frontal, temporal and occipital cortices, as well as the thalamus, 
striatum and cerebellum.  
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Conclusions: This study underlines the need to consider and assess for psychotic 
symptoms in the frontotemporal dementia-amyotrophic lateral sclerosis continuum 
particularly in those with C9orf72 gene expansions. The network of brain regions 
identified in this study is strikingly similar to that identified in other psychotic disorders 
such as schizophrenia, which suggests that treatment strategies in psychiatry may be 
beneficial for the management of psychotic symptoms in frontotemporal dementia.  
Keywords: Frontotemporal dementia, Amyotrophic lateral sclerosis, C9orf72 expansion, 
Psychosis, Schizophrenia, Neuroimaging  
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1. Introduction 
With the discovery and clinical descriptions of the C9orf72 gene expansion, it has become 
clear that such carriers may develop psychotic features and in some instances present with 
florid delusions or hallucinations (Snowden et al., 2012)
,
(Devenney et al., 2014). As such, we 
have seen renewed interest in psychosis in the Frontotemporal dementia-Amyotrophic lateral 
sclerosis (FTD-ALS) continuum, with recent systematic reviews of the literature suggesting 
that the prevalence is approximately 10-25% (Hall and Finger, 2015; Shinagawa et al., 2013). 
Neuroimaging studies of the C9orf72 expansion in both FTD and ALS have highlighted an 
excess of subcortical atrophy in comparison to non-carriers, and have led researchers to 
postulate that perhaps subcortical structures play a role in the generation of psychotic 
symptoms in C9orf72 cases but up until now this theory has not been explored (Bede et al., 
2013b; Downey et al., 2014; Mahoney et al., 2012). The largest body of evidence regarding 
psychosis and associated brain abnormalities comes from the literature in schizophrenia and 
related psychotic disorders, where abnormal changes in the volume, connectivity and 
function of the frontal and temporal cortices, thalamus and cerebellum have been reported 
(Andreasen et al., 1996; Byne et al., 2009; Fusar-Poli et al., 2012). These findings may be 
relevant to psychosis in FTD and FTD-ALS where similar cortical and subcortical regions are 
involved (Lillo et al., 2012). 
 
The present study aimed to improve our understanding of psychosis across a well-
characterised cohort of FTD and FTD-ALS patients, including a subset of C9orf72 carriers, 
by collecting prospective data using a validated behavioural tool in combination with a 
clinical interview. We then determined the underlying neural correlates of psychosis using 
structural neuroimaging techniques. It was hypothesised that, similar to other psychotic 
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disorders, and in line with imaging studies of C9orf72 patients, an extended network of 
cortical and subcortical regions would play a role in the generation of psychosis in FTD.  
 
2. Methods 
2.1 Participants 
In total 79 participants were included in the study; 36 consecutive patients with 
behavioural variant FTD (bvFTD) and 20 consecutive patients with bvFTD in 
combination with ALS (FTD-ALS) were matched by sex-, age- and education history to 
23 healthy controls. Patients were assessed at ForeFront, the Frontotemporal Dementia 
Research Group at Neuroscience Research Australia (NeuRA) and the Brain and Mind 
Centre, between 2008 and 2013. Healthy controls were selected from a volunteer panel at 
NeuRA. 
Diagnosis of bvFTD was made by an experienced clinical neurologist based on 
international diagnostic criteria for bvFTD (Rascovsky et al., 2011). ALS was diagnosed 
by an experienced clinical neurologist according to the El Escorial and Awajji diagnostic 
criteria(Brooks et al., 2000; Nodera et al., 2007). Global cognitive function was measured 
using the Addenbrooke’s Cognitive Examination-Revised (ACE-R)(Mioshi et al., 2006). 
Disease staging was assessed with the FTD Functional Rating Scale (FTD-FRS)(Mioshi et 
al., 2010).  
In each participant psychotic features began within a 10-year period prior to meeting 
consensus criteria for FTD. We intended to exclude participants if they were diagnosed 
with schizophrenia or another delusional disorder by a psychiatrist more than 10 years 
prior to presentation but this did not apply to these cases. Exclusion criteria also included a 
past history of traumatic brain injury, drug or alcohol abuse and cerebrovascular disease. 
None of the patients in the study were taking anti-psychotic medication or psychosis-
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inducing medication at the time of their initial assessments. Patients were not 
systematically assessed for hypoxia however this study was conducted at first presentation 
and at this stage none of the patients required non-invasive ventilation. 
Ethical approval was obtained from the South Eastern Sydney and Illawarra Area Health 
Service and the University of New South Wales ethics committees. All participants, or 
their responsible person, provided informed written consent in accordance with the 
Declaration of Helsinki. 
 
2.2 Genetic status 
All participants underwent blood sampling for the C9orf72 expansion. The repeat primed 
PCR was performed using the procedure described previously (Dobson-Stone et al., 2012), 
based on the protocol of Renton and colleagues (Renton et al., 2011). A patient's DNA 
sample was deemed positive for the C9orf72 repeat expansion if it contained an allele with 
> 30 repeats. Patients with a family history were also screened for other common genetic 
mutations (GRN, MAPT) by Sanger sequencing of genomic DNAs corresponding to all 
coding exons(Schofield et al., 2010; Stanford et al., 2003). 
 
2.3 Presence of delusions and hallucinations 
A delusion was defined as a false belief based on incorrect inference about external reality 
that is firmly sustained despite what almost everybody else believes and despite what 
constitutes incontrovertible and obvious proof or evidence to the contrary. The belief is 
not ordinarily accepted by other members of the person’s culture or subculture. A 
hallucination was defined as a perception of an external stimulus when none is present but 
which the person believes to be real (American Psychiatric Association, 2013).  
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The presence of delusions and hallucinations was determined in two ways. Firstly, the 
delusions and hallucinations subscale of the Neuropsychiatric Inventory (NPI)(Cummings 
et al., 1994) was completed with the carer. The subscales assess delusions and 
hallucinations separately with regards to frequency and severity of symptoms. Frequency 
is scored from 0-4; 0 = never, 1 = rarely – less than once per week, 2 = sometimes – about 
once per week, 3 = often – a few times per week, 4 = frequently – once or more per day. 
Severity is scored from 0-3; with 0 representing never, 1 = mild – produces little distress, 
2 = moderate – more disturbing to the patient but can be redirected by the caregiver, 3 = 
severe – very disturbing to the patient and difficult to redirect.  
During the visit, the nature of abnormal behaviours was clarified with the carer and 
patient, and re-scored according to the subscales of the NPI. A revised score was derived 
from the carer and patient interview. A total score was then generated for psychosis to 
reflect severity of psychotic symptoms by combining delusions (maximum 12) and 
hallucinations (maximum 12) scores for each participant and then expressing it as a 
percentage of the total score for delusions and hallucinations (maximum 24), referred to as 
the ‘Psychosis index’. 
 
2.4 Image acquisition and pre-processing 
All participants underwent whole-brain T1 imaging using a 3T Philips scanner with 
standard quadrature head coil. The 3D T1-weighted sequences were acquired as follows: 
coronal orientation, matrix 256 x256, 200 slices, 1 mm
2
 in-plane resolution, 1mm slice 
thickness, echo time/repetition time = 2.6/5.8 ms, flip angle 8
°
. MRI scans were obtained 
within 2 days of the clinical interview.   
Three-dimensional T1-weighted sequences were analysed with FSL-VBM 
(http://www.fmrib.ox.ac.uk/fsl/fslvbm/index.html) (Ashburner and Friston, 2000). 
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Structural images were brain-extracted using BET and tissue segmentation was carried out 
using FMRIB’s Automatic Segmentation Tool (FAST)(Zhang et al., 2001). The resulting 
grey matter partial volume maps were then aligned to the Montreal Neurological Institute 
standard space (MNI 152) using the non-linear registration approach (FNIRT) (Andersson 
et al., 2007) using a b-spline representation of the registration warp field(Rueckert et al., 
1999). A study-specific template was created and the native grey matter images were non-
linearly re-registered. The registered partial volume maps were modulated (to correct for 
local expansion or contraction) by dividing them by the Jacobian of the warp field. The 
modulated images were then smoothed with an isotropic Gaussian kernel with a standard 
deviation of 3mm (full-width at half-maximum: 8 mm).  
 
2.5 Statistical analyses  
Statistical analyses compared patients with controls irrespective of genetic status (bvFTD 
and FTD-ALS). Further comparisons between patients groups were carried out according 
to genetic status (C9orf72 carriers vs non-carriers) and presence or absence of psychotic 
features. 
 
2.5.2 Behavioral analyses 
Data were analyzed using SPSS 22.0 statistical package. Kolmogorov-Smirnoff tests were 
applied to determine if clinical and demographic variables were normally distributed. 
Parametric variables were analysed using univariate ANOVA, with post hoc analyses 
comparing differences across groups, using Sidak correction for multiple comparisons. 
Non-parametric data was analyzed using Mann-Whitney and the Kruskal-Wallis tests, and 
categorical data were compared with Chi-Square tests.  
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2.5.3 Voxel-based morphometry analyses 
First, atrophy analyses were carried out to identify differences in grey matter intensity 
between patients groups and healthy controls according to clinical diagnosis (bvFTD and 
FTD-ALS) and genotype (C9orf72 carriers vs non-carriers). Voxel-wise general linear 
models and t-tests were applied using permutation-based, non-parametric statistics, with 
5000 permutations per contrast (Nichols and Holmes, 2002). Significant clusters were 
defined at a t-threshold corrected for family-wise error of p < 0.05 with a minimum cluster 
size of 50 voxels. 
Next, correlations between psychosis index scores and grey matter intensity were 
investigated using an unbiased whole-brain approach. First, to uncover the neural 
correlates of psychosis in FTD, correlations between demeaned psychosis index scores 
and grey matter intensity were assessed combining all patients together (bvFTD, FTD-
ALS). Then, correlations between psychosis index and grey matter intensity were 
investigated, using the same analyses described above, in C9orf72 expansion carriers to 
identify neural correlates of psychosis specific to this genetic expansion. For all analyses, 
the statistical threshold was set at p < 0.005 uncorrected for multiple comparisons with a 
conservative cluster extent threshold of 25 voxels. This approach is designed to minimize 
Type I error while balancing the risk of Type II error (Lieberman and Cunningham, 2009). 
Anatomical locations of significant results were overlaid on the Montreal Neurological 
Institute (MNI) standard brain within the mricron software 
(http://www.mccauslandcenter.sc.edu/mricro/mricron/index.html), with maximum 
coordinates provided in MNI stereotaxic space. Anatomical labels were determined with 
reference to the Harvard-Oxford probabilistic cortical and subcortical atlases. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 10 
3. Results 
3.1 Demographics, cognitive and behavioural screening measures  
A comparison of the patient groups (bvFTD and FTD-ALS) with healthy controls revealed 
a higher ACE-R score for controls compared to patients. Otherwise there were no 
significant differences across the groups for age, sex and education years. Within the 
patient groups bvFTD patients scored lower in the FRS, indicating more functional 
impairment. Of the 56 patients included in the study 25% were C9orf72 expansion 
carriers. No patients carried GRN or MAPT mutations. Comparison between C9orf72 
carriers and non-carriers revealed no significant differences across demographic, cognitive 
and functional measures (all p > 0.05). 
 
Insert Table 1 here 
 
3.2 Psychotic Features 
3.2.1 Neuropsychiatric inventory  
Of the 56 patients, 34% showed psychotic features; 28% experienced delusions while 25% 
experienced hallucinations. There were no significant differences between patients with 
and without psychosis for all demographic variables (all p>0.05; Table e1). Furthermore, 
there were no significant differences between patients with and without psychosis, for NPI 
scores of disinhibition, apathy, depression, anxiety, agitation, elation, irritability, appetite 
or sleep (all p>0.1). 
 
Insert Supplementary Table e1 here 
 
3.2.2 Psychosis index 
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Exactly 64% of C9orf72 expansion carriers exhibited psychotic symptoms compared to 
26% of non-carriers (p=0.006).  The psychosis index was 12 in the overall patient cohort 
and was significantly higher in the C9orf72 positive cohort than the C9orf72 negative 
cohort (p=0.002; Table 2). 
 
**Insert Table 2 here 
 
3.2.3 Characterisation of psychosis 
Delusions were characterised according to their content and following accepted criteria 
(Kiran and Chaudhury, 2009). Persecutory delusions were the most common and were 
present in 63% of all affected patients. Somatic delusions (31%), delusions of a jealous 
nature (19%) and grandiose delusions (25%) were also present. In total, 38% of patients 
had a mixture of the above delusion types. 
Hallucinations were characterised according to modality. Auditory hallucinations were all 
in the second person and of a negative and persecutory nature. Visual hallucinations were 
either in the form of people, both alive and dead, or animals. Tactile hallucinations were of 
human touch in one and of insects crawling under the skin in another.  
Hallucinations and delusions in the C9orf72 cohort were similar to that seen in the patient 
cohort as a whole (Table 2), however there were no significant differences in the rate of 
hallucinations between carriers and non-carriers. Of note, somatic delusions were common 
in C9orf72 carriers and included medically unexplained sensory disturbances and 
abdominal pains. 
 
3.3 Neuroimaging Results  
3.3.1 Atrophy analyses 
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Group comparisons between clinical diagnoses and controls revealed the characteristic 
profiles of brain atrophy previously reported in bvFTD and FTD-ALS(Lillo et al., 2012). 
These results are presented in Supplementary Figure e1. In brief, both patient groups 
showed extensive overlap of grey matter density loss with widespread atrophy 
predominantly in frontal and temporal regions including the anterior insula, orbitofrontal 
cortex, striatum, thalamus and temporal poles. Parietal and occipital regions and the 
cerebellum were also involved. Direct comparisons between bvFTD and FTD-ALS 
revealed no significant regions of greater grey matter loss in either group.  
**Insert Supplementary Figure e1 here 
Consistent with previous studies in both FTD and ALS, patients with and without C9orf72 
expansions showed overlapping but distinct atrophy patterns (Bede et al., 2013a; Boeve et 
al., 2012; Mahoney et al., 2012; Whitwell et al., 2012). C9orf72 expansion carriers 
showed atrophy in bilateral anterior cingulate, dorsolateral and orbitofrontal prefrontal 
cortex, insular cortices and lateral parietal cortices, striatum and bilateral thalamus 
compared to healthy controls (Figure 1). Non-carriers exhibited similar but more extensive 
bilateral atrophy in the frontotemporal, insular, cingulate and striatal regions. C9orf72 
expansion carriers showed atrophy in bilateral precuneus and posterior cingulate cortex 
(not affected in C9orf72 non-carriers), whereas C9orf72 non-carriers (but not C9orf72 
expansion carriers) showed atrophy in the cerebellum. Direct comparisons between 
C9orf72 carriers and non-carriers did not reveal regions of significant differences between 
groups.  
**Insert Figure 1 here 
3.3.2 Neural correlates of psychosis  
A higher psychosis score for all participants combined (bvFTD and FTD-ALS) was 
associated with volume loss in a network of cortical and subcortical regions. The regions 
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implicated included the bilateral medial prefrontal and occipital cortices, and the right 
thalamus and the left cerebellum (Figure 2 and Supplementary Table e2). 
**Insert Figure 2 here 
**Insert Supplementary Table e2 here 
In C9orf72 expansion carriers, higher psychosis scores correlated with grey matter volume 
loss in a broader network of regions including bilateral medial frontal cortex, anterior 
cingulate cortex and orbitofrontal cortex, bilateral insula, caudate, putamen and thalamic 
nuclei, middle, inferior and superior temporal gyrus, temporal fusiform gyrus, lateral 
occipital cortex and right cerebellum (Figure 3 and Supplementary Table e3). 
**Insert Figure 3 here 
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4. Discussion 
Delusions and hallucinations in the FTD-ALS continuum have received renewed interest 
following the discovery of the C9orf72 expansion as the most common genetic 
abnormality in FTD and FTD-ALS(DeJesus-Hernandez et al., 2011; Renton et al., 2011). 
First, by means of a prospective study design, this study has confirmed that psychosis is 
common and can be more severe than previously recognised in patients with FTD. The 
rate of psychotic features was higher in C9orf72 carriers than non-carriers and these 
symptoms were more marked in such cases as reflected by the significantly higher 
psychosis index.  Of interest, this is the first study to explore the patterns of brain atrophy 
associated with psychosis in C9orf72 FTD-ALS. A distributed network of cortical and 
subcortical regions was identified, that included discrete regions of the frontal temporal 
and occipital cortices, as well as the thalamus, striatum and cerebellum. These patterns are 
strikingly similar to the changes seen in grey matter in schizophrenia and other psychotic 
disorders.  
Over one-third of the study cohort exhibited a degree of psychosis at first presentation, in 
contrast to previous studies where lower rates have been reported, and also slightly higher 
than recent systematic reviews have suggested (Hall and Finger, 2015; Shinagawa et al., 
2013), but in line with a recent study which identified psychotic symptoms in 32% of FTD 
patients by means of a retrospective chart review. This discrepancy may be partly 
explained by case selection; in our cohort we included only those with bvFTD and FTD-
ALS and in these cohorts psychosis is generally considered to be more common (Lillo et 
al., 2010). The use of a face-to-face focused carer and patient interview allowed for better 
delineation of symptoms. Of course the nature of referral patterns and referral bias to 
tertiary centres must always be taken into consideration and these results may not be 
readily transferrable to the population as a whole. Nonetheless, these results highlight the 
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extent of psychosis in FTD and particularly the need for more effective treatments for 
these symptoms. 
Overall, the delusions and hallucinations in these patients were largely negative in nature, 
and were not in keeping with the patients’ previous life experiences. It could be argued 
that these delusions represent confabulation related to frontal inhibitory dysfunction and 
‘filling in the gaps’ of memory loss which occurs in FTD (Mendez et al., 2008). The 
relative lack of grandiose delusions plus the pervasive nature of the delusions makes this 
unlikely. It is also difficult to differentiate true somatic hallucinations from medically 
unexplained symptoms, which often have a complex psychosocial basis. Moreover, 
abnormalities in perception, specifically auditory and temperature perception, related to 
underlying brain atrophy have been documented in these conditions (Fletcher et al., 2015; 
Hailstone et al., 2011). In the absence of more sensitive measures of psychosis it is 
difficult to determine the relationship between psychotic symptoms, medically 
unexplained symptoms and perceptual changes. Of interest is also the finding that the rate 
of hallucinations did not differ between carriers and non-carriers. This might merely 
reflect the relatively small numbers of patients with hallucinations but also suggests a 
disassociation between the mechanisms involved in the generation of delusions and 
hallucinations in FTD-ALS and warrants further study in a larger cohort. It has recently 
been reported that patients with ALS can experience non-psychotic primary psychiatric 
disorders years before the first diagnosis of ALS and while anecdotally a similar pattern is 
seen in patients with the C9orf72 expansion, this has not yet been systematically reviewed 
but might offer some insight into the underlying neurobiology which renders some 
patients more susceptible to developing psychiatric symptoms (Turner et al., 2016). 
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Until now the neural correlates of psychosis in FTD have been relatively unexplored. A 
recent study utilized pathological data to correlate regions of atrophy at post-mortem to 
psychotic symptoms reported at any time during life, and found an association with 
predominantly right-sided brain degeneration but failed to find any link with subcortical 
atrophy(Landqvist Waldö et al., 2015). Methodological differences may explain the 
divergent findings between this recent study and the current study. Although the current 
study did not have the benefit of pathological disease confirmation, a major strength is that 
after detailed clinical phenotyping each patient underwent MRI scanning within 2 days, 
therefore ensuring that the patterns of brain atrophy best reflected the symptoms 
experienced by the patient at that time. Furthermore, in the current cohort there were no 
differences between patients who experienced psychotic symptoms and those who did not 
in terms of other abnormal behaviours, such as disinhibition and apathy, suggesting that 
the results are not driven by other behavioural factors.  
The association of a network of cortical and subcortical atrophy with increased psychosis 
scores in C9orf72 is new and a key finding of this study. The findings are exploratory 
however they do converge with the hypothesis of Downey and colleagues who showed 
that C9orf72 carriers have an altered body schema (Downey et al., 2014). These authors 
suggested that altered body schema deficits might contribute to the development of 
psychosis generation in C9orf72 carriers through alterations in thalamo-cortico-cerebellar 
networks. The regions of atrophy identified here are remarkably similar to those identified 
consistently in meta-analyses of VBM studies of schizophrenia and other psychotic 
disorders including schizoaffective disorder and first-episode psychosis(Amann et al., 
2016; Bora et al., 2011; Glahn et al., 2008). Similar to our findings, these meta-analyses 
repeatedly show atrophy of key temporal lobe structures including the superior temporal 
gyrus, which has also been linked with positive symptoms and in particular auditory 
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hallucinations in schizophrenia(Aguayo, 1990). Atrophy of the insular and anterior 
cingulate cortex are associated with higher psychosis scores in our cohort and again these 
regions, which are key structures of the salience network with links to the superior 
temporal pole, the dorsolateral prefrontal cortex, thalamus, and the striatum(Seeley et al., 
2007), are shown to be atrophied across multiple VBM studies in psychotic 
syndromes(Amann et al., 2016; Bora et al., 2011; Glahn et al., 2008). The salience 
network is involved in detection, analysis and integration of emotionally salient stimuli 
with respect to the internal environment and is implicated in symptom generation in both 
FTD and schizophrenia(Seeley et al., 2007; Zhou and Seeley, 2014). Similarly, and 
consistent with the findings from this study, within the frontal cortex the medial frontal 
region is characteristically abnormal in psychotic disorders. That the thalamus has been 
repeatedly implicated in psychotic disorders converges well with previous imaging 
findings in C9orf72 carriers, which showed thalamic atrophy, and thalamic involvement in 
functional networks(Lee et al., 2014; Mahoney et al., 2012).  
This study has limitations. Replication in a larger cohort is necessary to increase statistical 
power and confirm the findings, although given the relative rarity of these conditions this 
can be difficult, which in turn points to the need for multicentre collaborations. The 
neuroimaging findings, although novel, are preliminary and further neuroimaging projects 
should include methods of analysing network connectivity to confirm if dysfunctions 
within large-scale brain networks are responsible for psychosis in FTD. It is also important 
to note that subregions within subcortical structures, such as the thalamus, have distinct 
functions and map to specific cortical region. Analysis of these subregions was beyond the 
scope of this study but should be considered for future projects. Furthermore, analysis of 
delusions and hallucinations separately would have been ideal, as it is possible that these 
two symptoms may have different neural circuitry. However the small sample size 
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restricted further analysis and therefore was outside the scope of this project but should be 
performed in a larger cohort in future studies. 
In conclusion, psychotic symptoms are common in the FTD-ALS continuum, and should 
be assessed by means of a detailed carer and patient interview. The commonalities 
between primary psychotic disorders and the FTD-ALS continuum in terms of underlying 
neural substrates are notable, and in line with current views that brain network 
degeneration may be responsible for shared behavioural symptoms between schizophrenia 
and FTD(Zhou and Seeley, 2014), which further suggests that we may be able to 
incorporate patient management strategies from psychiatry. Finally, we suggest that an 
objective measure to characterise psychotic symptoms will be useful as well as targeted 
studies using functional MRI to gain further insight into the brain networks involved. 
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Figure Legends 
Figure 1 Heading: Regions of brain atrophy in C9orf72 carriers and non-carriers compared 
to healthy controls.  
Figure 1 Legend: Group results from voxel-based morphometry analyses demonstrating 
areas of decreased grey matter density in C9orf72 positive (blue) and C9orf72 negative 
(yellow) relative to healthy controls. Patient groups showed extensive overlapping atrophy 
(green). Significant clusters were defined at a t-threshold corrected for family-wise error of p 
< 0.05 with a minimum cluster size of 50 voxels. No significant clusters were identified in 
direct comparisons between negative and positive C9orf72 patients. The statistical maps are 
superimposed on the Montreal Neurological Institute template brain. Images are displayed in 
radiological convention (the left side of images corresponds to the right side of the brain). C9 
pos = C9orf72 positive; C9 neg = C9orf72 negative; HC = healthy controls. 
Figure 2 Heading: Neural correlates of psychosis in the FTD-ALS continuum. 
Figure 2 Legend: Results from voxel-based morphometry analyses demonstrating 
correlations between psychosis index and areas of grey matter density in the whole FTD-ALS 
cohort. The statistical maps are superimposed on the Montreal Neurological Institute 
template brain. Coloured voxels show regions that were significant in the analyses (p < 0.005 
uncorrected).  Images are displayed in radiological convention (the left side of image 
corresponds to the right side of the brain). 
Figure 3 Heading: Neural correlates of psychosis in C9orf72 expansion carriers. 
Figure 3 Legend: Results from voxel-based morphometry analyses demonstrating 
correlations between psychosis index and areas of grey matter density in C9orf72 expansion 
carriers. The statistical maps are superimposed on the Montreal Neurological Institute 
template brain.  Coloured voxels show regions that were significant in the analyses (p < 0.005 
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uncorrected). Images are displayed in radiological convention (the left side of image 
corresponds to the right side of the brain).  
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Table 1. Demographics and clinical characteristics in bvFTD, FTD-ALS and healthy controls, and C9orf72 carriers and non-carriers  
 
Values are expressed as mean ± standard deviation. bvFTD = behavioural variant frontotemporal dementia; FTD-ALS = frontotemporal 
dementia – amyotrophic lateral sclerosis; HC = healthy controls; ACE-R = Addenbrooke’s Cognitive Examination – Revised; FRS = Functional 
dementia Rating Scale. ^The FRS provides logit scores ranging from 4.12 (very mild) to -4.99 (very severe). * Denotes significant differences at 
the p < 0.05 level. ** Denotes significant differences at the p < 0.001 level. 
 
 
 
 
 
 bvFTD 
(n =36) 
FTD-ALS 
(n=20) 
HC 
(n=23) 
p value Post-hoc C9orf72  
carriers 
(n=14) 
C9orf72 
Non-carriers 
(n=42) 
p value 
C9orf72 positive, 
n (%) 
9 (25%) 5 (25%) 0 - - - - - 
Sex (M:F) 26:12 13:7 14:9 0.65 - 11:3 28:14 0.5 
Age (years)  59 ± 7.2 60.6 ± 6.6 62.5 ± 3.9 0.37 - 61.2 ± 5.9 59.1 ± 7.1 0.4 
Education (years) 12.8 ± 3.4 12.6 ± 3.0 12.6 ± 2.9 0.47 - 12.6 ± 2.8 12.8 ± 3.5 0.83 
Disease duration 
(years) 
3.7 ± 2.4 2.5 ± 1.2 - 0.08 - 4.2 ± 2.6 3.1 ± 2.0 0.2 
ACE-R (max 100) 73.5 ± 13.4 68.7 ± 12.3 94.1 ± 3.8 < 0.001** HC > 
bvFTD, 
FTD-ALS 
73.8 ± 17.1 71.7 ± 12.5 0.3 
FRS Rasch score^ -0.7 ± 1.3 0.7 ± 1.7 - 0.007* - -0.03 ± 1.7 -0.34 ± 1.6 .72 
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Table 2. Psychosis scores and characterisation of psychotic symptoms in C9orf72 positive and negative patients 
 C9orf72 positive 
(n=14) 
C9orf72 negative 
(n=42) 
p value 
Psychosis score 5.3 ± 5.3 1.9 ± 4.6 0.002* 
Psychosis index 24.3 ± 22 7.7 ± 19.5 0.002* 
Psychotic symptoms, n (%) 9 (64) 11 (26) 0.006* 
Delusions  8 (57) 8 (19) 0.006* 
Persecutory 4 (29) 6 (14) 0.04* 
Somatic 3 (21) 2 (5) 0.06 
Jealous 2 (14) 1 (2) 0.08 
Grandiose 2 (14) 2 (5) 0.23 
Hallucinations  5 (36) 9 (17) 0.133 
Auditory 3 (21) 2 (5) 0.06 
Visual 2 (14) 3 (7) 0.42 
Somatic 1 (7) 1 (2) 0.41 
Values are expressed as mean ± standard deviation. * Denotes significant differences at the p < 0.05 level.  
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Fig. 1 
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Fig. 2 
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Fig. 3 
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Highlights 
This study has confirmed a high rate of psychotic symptoms in C9orf72 carriers. In total 64% of C9orf72 carriers exhibited psychotic symptoms at 
presentation. 
 
Psychotic symptoms are also common in C9orf72 non-carriers. Altogether 26% of non-carriers experienced psychotic symptoms. 
 
Psychotic symptoms are more severe in C9orf72 carriers than non-carriers, as demonstrated by a higher psychosis score in carriers.  
 
This prospective cohort study identified that a distributed cortical and subcortical network that included discrete regions of the frontal, temporal and occipital 
cortices, as well as the thalamus, striatum and cerebellum was associated with increased psychotic symptoms in C9orf72 expansion carriers.  
 
The network of brain regions identified in this study are strikingly similar to those identified in other psychotic disorders such as schizophrenia, which 
suggests that treatment strategies in psychiatry may be beneficial for the management of psychotic symptoms in C9orf72 and frontotemporal dementia.  
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